Statistical analysis revealed that this group is significantly enriched with ER-negative, PR-negative, HER2-negative, or triple negative breast cancer (ER-, PR-, HER2- or TNBC) patients. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.